Insulet (NASDAQ:PODD) is a medical device company that develops and sells the Omnipod system. This system is a tubeless insulin pump designed for people with diabetes, offering a different way to manage their condition. The company faces competition from other insulin pump makers and, more recently, from the growing market for weight-loss drugs.
An analyst from Raymond James has adjusted the price target for Insulet, lowering it to $216 from a previous target of $263. When this new target was announced, the stock was trading at $151.51. This updated target represents a potential upside of approximately 42.56% from the price at the time of the report.
Despite the stock's recent struggles, Insulet shows strong financial growth. For the first quarter of 2026, it reported revenue of $761.70 million, a 33.90% increase from the year before. Its adjusted earnings per share (EPS) of $1.42 also grew by 39.70%, beating the Zacks Consensus Estimate, as highlighted by Zacks.
The stock's performance has been volatile, dropping 45.90% year-to-date. In the last four weeks alone, shares fell 17.80%. An analysis from Zacks Investment Research gives Insulet a short-term "Hold" rating. This analysis sets a sales-based target of $163, questioning if its growth can overcome market uncertainty in 2026.
Looking ahead, Insulet's management has raised its 2026 outlook. The company now projects revenue growth between 21% and 23%. It also expects its adjusted EPS, a measure of profitability per share, to climb by over 25%. This growth is expected to come from the adoption of its Omnipod 5 system.
